science wire

« BACK

Pharmacology



Results 1501 - 1550 of 1554.
« Previous 1 ... 27 28 29 30 31 ... 32 Next »


Pharmacology - Health - 27.05.2010
Novartis Phase III trial examining EPO906 (patupilone) for patients with advanced ovarian cancer failed to meet primary endpoint
Novartis Phase III trial examining EPO906 (patupilone) for patients with advanced ovarian cancer failed to meet primary endpoint Basel, May 27, 2010 - Novartis announced today that patupilone (EPO906) did not show a significant overall survival advantage in a phase III trial of patients with advanced ovarian cancer, refractory or resistant to platinum-based therapy The comparator arm in the trial was Doxil /Caelyx (pegylated liposomal doxorubicin).

Pharmacology - 25.05.2010
Novartis announces extension of US regulatory priority review period for FTY720, an investigational once-daily oral multiple sclerosis therapy
Novartis announces extension of US regulatory priority review period for FTY720, an investigational once-daily oral multiple sclerosis therapy US Food and Drug Administration (FDA) extends priority r

Health - Pharmacology - 22.05.2010
Ranibizumab significantly more effective than standard of care in treating vision loss due to DME, a serious complication of diabetes
Ranibizumab significantly more effective than standard of care in treating vision loss due to DME, a serious complication of diabetes Study shows around 40% of ranibizumab patients substantially impr

Health - Pharmacology - 23.04.2010
Novartis gains new indication for Diovan for the treatment of children and adolescents with high blood pressure in the EU
Novartis gains new indication for Diovan for the treatment of children and adolescents with high blood pressure in the EU New indication brings the world's number one selling high blood pressure medi

Pharmacology - Health - 22.04.2010
Novartis receives US FDA approval for Zortress® (everolimus) to prevent organ rejection in adult kidney transplant recipients
Novartis receives US FDA approval for Zortress® (everolimus) to prevent organ rejection in adult kidney transplant recipients Zortress offers kidney transplant recipients a new option for preventing

Pharmacology - 22.04.2010
Novartis receives US FDA approval for Zortress (everolimus) to prevent organ rejection in adult kidney transplant recipients
Novartis receives US FDA approval for Zortress (everolimus) to prevent organ rejection in adult kidney transplant recipients Zortress offers kidney transplant recipients a new option for preventing o

Pharmacology - 20.04.2010
Novartis healthcare portfolio generates strong growth in first quarter of 2010, progress on delivering innovation, growth and productivity
Novartis healthcare portfolio generates strong growth in first quarter of 2010, progress on delivering innovation , growth and productivity Net sales up 25% (+18% in constant currencies, or cc) to US

Pharmacology - 19.04.2010
Sandoz to acquire Oriel Therapeutics, gaining rights to portfolio of respiratory products targeting asthma and COPD
Sandoz to acquire Oriel Therapeutics, gaining rights to portfolio of respiratory products targeting asthma and COPD ·         Sandoz gains rights to three promising development projects, as well as t

Pharmacology - Health - 13.04.2010
Novartis investigational multiple sclerosis therapy Gilenia®* (FTY720) shown to reduce relapse rates regardless of treatment history
Basel, April 13, 2010 - Data presented at the American Academy of Neurology (AAN) annual meeting add to the accumulating evidence of the positive benefit/risk profile of Gilenia, a potential first-in-class, once-daily oral therapy for relapsing forms of multiple sclerosis (MS).

Pharmacology - Health - 13.04.2010
Novartis investigational multiple sclerosis therapy Gilenia * (FTY720) shown to reduce relapse rates regardless of treatment history
Novartis investigational multiple sclerosis therapy Gilenia * (FTY720) shown to reduce relapse rates regardless of treatment history New extension data show Gilenia effect sustained over two years; also highlights potential benefits of switching from interferon beta-1a Basel, April 13, 2010 - Data presented at the American Academy of Neurology (AAN) annual meeting add to the accumulating evidence of the positive benefit/risk profile of Gilenia, a potential first-in-class, once-daily oral therapy for relapsing forms of multiple sclerosis (MS).

Pharmacology - 18.03.2010
Novartis receives approval in the European Union for Menveo®, first quadrivalent conjugate vaccine in the EU to help prevent meningococcal disease
Basel, March 18, 2010 - Novartis announced today that the European Commission (EC) granted a Marketing Authorization for Menveo ® (Meningococcal Group A, C, W135 and Y conjugate vaccine) in all 27 European member states. Menveo is indicated for the active immunization of adolescents (from 11 years of age) and adults at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y, to prevent invasive disease.

Health - Pharmacology - 18.03.2010
Novartis receives approval in the European Union for Menveo , first quadrivalent conjugate vaccine in the EU to help prevent meningococcal disease
Novartis receives approval in the European Union for Menveo , first quadrivalent conjugate vaccine in the EU to help prevent meningococcal disease Meningococcal disease is a major cause of bacterial

Pharmacology - 16.03.2010
Exploratory trial shows no incremental benefit of aliskiren add-on therapy in improving changes to cardiac shape in heart attack patients
Exploratory trial shows no incremental benefit of aliskiren add-on therapy in improving changes to cardiac shape in heart attack patients ·       Trial assessed addition of aliskiren to help limit changes to the heart's shape and function in patients after heart attack (post-myocardial infarction) ·       A small numerical reduction in cardiac volume from adding aliskiren to standard therapy seen in echocardiogram results, but not statistically

Pharmacology - 14.03.2010
NAVIGATOR shows valsartan delayed progression to type 2 diabetes in at-risk cardiovascular patients with impaired glucose tolerance
NAVIGATOR shows valsartan delayed progression to type 2 diabetes in at-risk cardiovascular patients with impaired glucose tolerance NAVIGATOR study involved more than 9,000 patients, making it one of the largest and longest global trials to date in pre-diabetic patients Basel, March 14, 2010 - Results from a landmark study involving more than 9,000 people showed that the high blood pressure medicine valsartan delayed progression to type 2 diabetes in patients with cardiovascular disease or risk factors and impaired glucose tolerance (IGT), a common pre-diabetic condition.

Pharmacology - 10.03.2010
Novartis announces USD 5 billion bond issue
These notes are registered with the U.S. Securities and Exchange Commission under an automatic shelf registration statement filed by Novartis in 2008.

Business / Economics - Pharmacology - 26.02.2010
Shareholders approve all proposed resolutions of Novartis Board of Directors
Shareholders approve 14 th consecutive dividend increase to CHF 2.20 (+5%) per share for 2010, representing a payout of approximately 55% of net income from continuing operations, marking cont

Pharmacology - 22.02.2010
Novartis receives FDA approval of Menveo®, a vaccine to prevent meningococcal disease
Basel, February 22, 2010 - Novartis announced that Menveo® (Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine), a quadrivalent meningococcal conjugate vaccine was approved by the US Food and Drug Administration (FDA) for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135 in people 11 to 55 years of age[1].

Pharmacology - 22.02.2010
Novartis oral multiple sclerosis development compound Gilenia®* (FTY720) granted US priority review status
Basel, February 22, 2010 - Gilenia®* (FTY720, fingolimod) has been granted priority review status by the US Food and Drug Administration (FDA), which accepted the regulatory submission made in December 2009 for this medicine. Once-daily Gilenia  (0.5 mg) has the potential to become the first approved oral therapy for the treatment of multiple sclerosis (MS).

Pharmacology - 19.02.2010
Novartis drug Tasigna® receives FDA priority review for newly diagnosed patients with early-stage chronic myeloid leukemia
Basel, February 19, 2010 - Novartis announced today that Tasigna® (nilotinib) has been granted priority review by the US Food and Drug Administration (FDA) for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. FDA priority review status is granted to therapies that offer major advances in treatment or provide a treatment where no adequate therapy exists.

Pharmacology - 09.02.2010
Novartis gains exclusive rights to Debio 025, an antiviral agent in Phase IIb development as potential first-in-class hepatitis C therapy
Phase II results demonstrate efficacy of Debio 025, a cyclophilin inhibitor, against hepatitis C virus when used alone or in combination with current standard therapy 1 Basel, February 9, 2010 - Novartis has gained exclusive rights to develop and market Debio 025 (alisporivir), a potential first-in-class antiviral agent currently in Phase IIb development for the treatment of hepatitis C. Debio 025 is the first in a new class of drugs called cyclophilin inhibitors which could become part of the future standard of care for the disease.

Health - Pharmacology - 27.01.2010
Ein fataler Kreislauf
Zurich - University of Zurich Eine Studie der Psychiatrischen Universitätsklinik Zürich hat erstmals die Schweizer Drogenpolitik von 1975 bis 2007 untersucht.

Pharmacology - 27.01.2010
Repression und Heroinbehandlungen beeinflussen Zahl der Drogentoten
Zurich - University of Zurich Die polizeiliche Repression gegen Heroinkonsumenten war in den neunziger Jahren besonders hoch.

Pharmacology - 26.01.2010
Novartis achieves record results in 2009 as momentum from recently launched products drives growth across its entire healthcare portfolio
o     Net sales rise 11% in local currencies (lc) to USD 44.3 billion (+7% in USD), as innovative   products drive Pharmaceuticals to industry-leading growth and Vaccines and Diagnostics sells

Health - Pharmacology - 26.01.2010
Die Ergotherapie von morgen findet am Computer statt
Zurich - University of Zurich Nach Hirnverletzungen müssen Patienten Bewegungen neu einüben. Neuerdings helfen ihnen dabei Computergames.

Pharmacology - Health - 20.01.2010
Novartis oral MS therapy FTY720 shows reduced risk of confirmed disability progression as published in New England Journal of Medicine
Results of the TRANSFORMS[1] and FREEDOMS[2] studies, the two pivotal Phase III clinical trials with oral FTY720 (fingolimod), have been published in The New England Journal of Medicine , providing c

Health - Pharmacology - 20.01.2010
Three new Novartis medicines approved in Japan for patients with type 2 diabetes, high blood pressure and advanced kidney cancer
Basel - Novartis Basel, January 20, 2010 - Patients in Japan will benefit from the approval of three new Novartis medicines - Equa® (vildagliptin), marketed as Galvus® in the European Union , for t

Pharmacology - Business / Economics - 18.01.2010
Novartis providing equivalent of over USD 2.5 million in immediate emergency aid for victims of Haiti earthquake
Basel - Novartis Through its local organizations in countries throughout the region, Novartis is providing the equivalent of over USD 2.5 million in immediate emergency aid for victims of the recent earthquake in Haiti.

Pharmacology - Physics - 18.01.2010
Attacking the lifeline of tumour cells
Attacking the lifeline of tumour cells
A Finnish-Swiss team cracks the atomic structure of a major cancer drug target Researchers at Biomedicum Helsinki, Finland, and the Paul Scherrer Institute (PSI) in Villigen, Switzerland, have determined the crystal structure of the ligand-binding domain of a vascular endothelial growth factor (VEGF) receptor in complex with one of its ligands (VEGF-C).

Health - Pharmacology - 13.01.2010
Mikro-Teile gegen Anämie
Zurich - University of Zurich Für Hämoglobin-Erbkrankheiten gibt es gute Therapien. Weiterhin ist aber ein Teil der Patienten auf regelmässige Transfusionen angewiesen.

Pharmacology - Health - 11.01.2010
Novartis launches schizophrenia treatment Fanapt in the US, offering patients an attractive alternative to existing medications
"Schizophrenia remains one of the most debilitating and difficult to treat mental illnesses.

Pharmacology - Health - 23.12.2009
Novartis to acquire Corthera Inc., gaining worldwide rights to Phase III project relaxin for treatment of acute decompensated heart failure
Basel - Novartis - Novartis will gain exclusive worldwide rights to relaxin, a recombinant version of a naturally occurring human peptide, through the acquisition of the privately held US biopharmaceutical company Corthera Inc.

Health - Pharmacology - 21.12.2009
All three Novartis A(H1N1) 2009 influenza vaccines prequalified by World Health Organization (WHO) for use in developing world
Basel - Novartis WHO prequalification facilitates purchasing through UN agencies and thus enhances access for developing world countries to Novartis A(H1N1) 2009 vaccines that meet unified standards of quality and safety.

Health - Pharmacology - 18.12.2009
Novartis meningococcal vaccine Menveo® recommended for approval in the European Union for prevention of disease in adolescents and adults
Basel - Novartis (Meningococcal Group A, C, W-135 and Y-CRM Conjugate Vaccine) has received a Positive Opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA).

Pharmacology - Health - 09.12.2009
Novartis set to sustain its leading global position in oncology with portfolio targeting various tumors and life-threatening diseases
09.12.2009 / Basel - Novartis Basel, December 9, 2009 - Novartis is set to sustain its leading global position in oncology by expanding the range of indications for several marketed the

Pharmacology - Health - 08.12.2009
Novartis Tasigna® trial shows superior results to Glivec® in patients with early-stage chronic myeloid leukemia
08.12.2009 / Basel - Novartis At 12-month milestone, significantly fewer patients progressed to accelerated or blastic phase on Tasigna 300 mg twice daily than on Glivec 400 mg once dai

Pharmacology - Health - 03.12.2009
Novartis receives approval in the European Union for Onbrez® Breezhaler®, a new once-daily bronchodilator for patients with COPD
03.12.2009 / Basel - Novartis Basel, December 3, 2009 - Novartis announced today that the European Commission (EC) has approved Onbrez Breezhaler (QAB149 or indacaterol) in both 150 mcg

Health - Pharmacology - 02.12.2009
Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting
02.12.2009 / Basel - Novartis Basel, December 2, 2009 - Novartis announced today that new data, including a late-breaking presentation on Tasigna"(nilotinib) in a form of chronic myeloi

Pharmacology - Health - 25.11.2009
Novartis gains rights to two oral targeted investigational therapies focusing on patients with life-threatening blood disorders and cancers
25.11.2009 / Basel - Novartis Ex-US rights acquired for JAK inhibitor INCB18424 in Phase III development as first-in-class treatment for myelofibrosis, a life-threatening blood disorder

Health - Pharmacology - 24.11.2009
Novartis inaugurates large-scale US based cell-culture influenza vaccine manufacturing facility
24.11.2009 / Basel - Novartis Facility designed to supply 150 million doses of pandemic vaccine within 6 months of influenza pandemic declaration; facility ready to respond to a pandemi

Health - Pharmacology - 17.11.2009
Novartis Influenza A(H1N1) 2009 vaccine US interim data show lower doses of antigen may suffice to generate a protective immune response against A(H1N1)
17.11.2009 / Basel - Novartis Interim clinical data from approximately 4,000 individuals suggest that half a dose of the currently US-approved Novartis unadjuvanted Influenza A(H1N1) 20

Health - Pharmacology - 13.11.2009
Novartis receives approval in Switzerland for Celtura®, a cell culture-based Influenza A(H1N1) pandemic vaccine
13.11.2009 / Basel - Novartis Approvals in Germany and Switzerland demonstrate expanded adoption of new cell culture technology - an important milestone in replacing 50 year-old egg-bas

Pharmacology - Health - 12.11.2009
Novartis launches Prevacid®24HR over-the-counter for full 24-hour frequent heartburn treatment
12.11.2009 / Basel - Novartis Prevacid®24HR provides America 's 50 million frequent heartburn sufferers[1] with convenient and easy accessibility to this effective heartburn treatment

Health - Pharmacology - 05.11.2009
Novartis receives regulatory approval in Germany for Celtura®, a cell culture-based Influenza A(H1N1) pandemic vaccine
05.11.2009 / Basel - Novartis Clinical trials in more than 1,850 individuals across all age groups show strong efficacy, that can induce immune responses associated with protection agai

Business / Economics - Pharmacology - 04.11.2009
Novartis to expand its human vaccines presence in China through proposed acquisition of a majority stake in Zhejiang Tianyuan
04.11.2009 / Basel - Novartis Basel, November 4, 2009 - Novartis has reached an agreement to acquire an 85% stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical Co.

Pharmacology - Business / Economics - 03.11.2009
Novartis announces USD 1 billion investment to build largest pharmaceutical R&D institute in China
03.11.2009 / Basel - Novartis Additional USD 250 million invested in advanced technical R&D and manufacturing facility opening in Changshu, furthering economic development of Jiangs

Health - Pharmacology - 29.10.2009
Novartis on track to deliver Influenza A (H1N1) vaccine for the US
29.10.2009 / Basel - Novartis To date, Novartis has shipped more than 7.5 million doses of Influenza A (H1N1) vaccines in multi-dose vials and pre-filled syringes ready to use, a

Health - Pharmacology - 28.10.2009
Novartis biological drug Ilaris® approved in EU to treat children and adults with CAPS, a rare debilitating auto-inflammatory disease
28.10.2009 / Basel - Novartis Ilaris is a monoclonal antibody that selectively targets and blocks interleukin-1 beta (IL-1ß), the trigger for inflammation and tissue damage in CAPS pat

Pharmacology - Health - 23.10.2009
Novartis receives approval in the European Union for Exforge HCT®, a new 3-in-1 treatment for high blood pressure
23.10.2009 / Basel - Novartis Basel , October 23, 2009 - The European Commission has granted Novartis marketing authorization for Exforge HCT" a new 3-in-1 treatment for people with high blood pressure.

Health - Pharmacology - 22.10.2009
Novartis delivers strong new product momentum and operational performance in first nine months of 2009
22.10.2009 / Basel - Novartis Net income of USD 6.1 billion down 8% due to negative currency impact, Alcon-related financing costs and USD 189 million of associated companies cha

Health - Pharmacology - 20.10.2009
New Phase II data show ACZ885 gave better pain relief and flare prevention for patients with chronic gout than an injectable corticosteroid
20.10.2009 / Basel - Novartis Basel, October 20, 2009 - New Phase II results show that the novel biological therapy ACZ885 (canakinumab) is significantly more effective than an injectab
« Previous 1 ... 27 28 29 30 31 ... 32 Next »

This site uses cookies and analysis tools to improve the usability of the site. More information. |